Bezisterim (developmental code names NE3107, HE3286) is a synthetic analogue of androstenetriol that is believed to have anti-inflammatory and insulin-sensitizing effects in the brain. The compound crosses the bloodâÂÂbrain barrier and does not activate any neurotransmitter receptors. It has been tested as a treatment for Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The drug is under development for a variety of conditions and its highest developmental phase is phase 3 for Alzheimer's disease.